Overview

This study is an investigator-initiated prospective, single-center, open-label clinical trial designed to evaluate the clinical efficacy and safety of Lusutrombopag in promoting platelet remodeling after allogeneic hematopoietic stem cell transplantation in patients with hematologic disorders.

Eligibility

Inclusion Criteria:

Participants must meet the following criteria:

1. The patient signed an informed consent form and voluntarily participated in the study.
2. Patients undergoing HLA haploidentical allogeneic hematopoietic stem cell transplantation;
3. Age ≥18 years, regardless of gender
4. ECOG score 0-2
5. Expected survival ≥3 months
6. No severe impairment of function of major organs

Exclusion Criteria:

If any of the following criteria are met, the participants must be excluded from this research project:

1\) Patients with known allergy to TPO-RAs; 2) Patients who cannot take oral medication due to gastrointestinal symptoms, altered mental status, etc. during transplantation; 3) Other reasons for exclusion as determined by the investigator.

\-